Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

Completed · Phase 3

Conditions studied: Attention-Deficit/Hyperactivity Disorder

In brief

This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy. The study will also test the safety of Lisdexamfetamine Dimesylate and how well it works.

Key facts

Study ID

NCT01106430

Run by

Shire

People needed

267

Starts

2010-06-28

Expected to finish

2012-07-19

Last updated by the study team

2021-06-11

Who can join

Age: 6 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has had an historical or current inadequate response to methylphenidate (MPH) treatment. Inadequate response includes but is not limited to the presence of some residual symptoms, with associated impairment inadequate duration of action and/or variability of symptom control, and/or Investigator feels that the subject may derive benefit from an alternative drug treatment to MPH therapy.
• Subject is a male or female aged 6-17 years inclusive at the time of consent
• Subject must meet Diagnostic and Statistical Manual of Mental Disorders, fourth edition. - Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation
• Subject must have a baseline ADHD-RS-IV total score 28.

You may not qualify if…

• Subject has taken more than 1 MPH treatment (for example, 2 or more different MPH treatments). Examples include but are not limited to RITALIN immediate release (IR) and EQUASYM IR; MEDIKINET IR and CONCERTA; RITALIN long-acting LA and CONCERTA. Note: this does not include subjects who have taken IR MPH for dose titration on a short-term basis (for example, £4 weeks) with an adequate response
• In the Investigator's judgement, subject has failed to respond to more than 1 previous course(s) of MPH treatment. Failure to respond includes worsening of symptoms or no change/minimal improvement of symptoms.
• Subject has previously been exposed to STRATTERA or to amphetamine therapy
• Subject has previously demonstrated intolerable side effects to 1 MPH treatment which limited titration to acceptable efficacy or that required a decrease in dose resulting in unacceptable tolerability and/or efficacy
• Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining physician, will contraindicate treatment with SPD489 or STRATTERA or confound efficacy or safety assessments.
• Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.

Where it is running

• Clinical Study Centers, LLC — Little Rock, Arkansas, United States
• Shanti Clinical Trials — Colton, California, United States
• Psychiatric Centers at San Diego Feighner Research — San Diego, California, United States
• Elite Clinical Trials, Inc. — Wildomar, California, United States
• Sarkis Clinical Trials — Gainesville, Florida, United States
• Amedica Research Institute, Inc. — Hialeah, Florida, United States
• Fidelity Clinical Research, Inc. — Lauderhill, Florida, United States
• Clinical Neuroscience Solutions, INC — Orlando, Florida, United States
• Northwest Behavioral Research Center — Roswell, Georgia, United States
• Capstone Clinical Research — Libertyville, Illinois, United States
• Baber Psychiatric Associates — Naperville, Illinois, United States
• Clinco — Terre Haute, Indiana, United States
• Heartland Research Associates, LLC — Wichita, Kansas, United States
• Four Rivers Clinical Research, Inc — Paducah, Kentucky, United States
• Louisianna Research Associates — New Orleans, Louisiana, United States
• Office of Marc Hertzman, MD, PC — Rockville, Maryland, United States
• Rochester Center for Behavioral Medicine — Rochester Hills, Michigan, United States
• Midwest Research Group/Saint Charles Psychiatric Associates — Saint Charles, Missouri, United States
• Premier Psychiatric Research Institute, LLC — Lincoln, Nebraska, United States
• Center for Psychiatry and Behavioral Medicine, Inc. — Las Vegas, Nevada, United States
• Children's Specialized Hospital — Toms River, New Jersey, United States
• Richmond Behavioral Associates — Staten Island, New York, United States
• Triangle Neuropsychiatry, PLLC — Durham, North Carolina, United States
• Innovis Health — Fargo, North Dakota, United States
• Harmonex Neuroscience Research, Inc — Dothan, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.